Displaying 67 (all) recruiting clinical trials.
-
A Phase 3 Multicenter Open-label Randomized 2 Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This is a Phase 3 study for patients with Pancreatic Ductal Adenocarcinoma (PDAC) whose cancer has been removed by surgery. The study is randomized and ...
Phase
Interventional
-
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI an IMiD and an Anti-CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
This is a Phase 3 study testing a new treatment for adult men with metastatic castration-resistant prostate cancer (mCRPC) who have already progressed after treatment ...
Phase
Interventional
-
A Phase 3 Randomized Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This is a Phase 3 study testing how safe and effective a new drug combination is for people with metastatic pancreatic cancer (PDAC) who have ...
Phase
Interventional
-
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
This is a Phase 3 study comparing how well JNJ-79635322 works compared with teclistamab in people with relapsed or refractory multiple myeloma (RRMM), a blood ...
Phase
Interventional
-
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
This study is being done to see if the overall survival or improvement of the recurrence-free survival from cervical cancer can be increased by adding ...Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
This is a Phase 3 randomized, open-label study testing the investigational drug Rinatabart Sesutecan (Rina-S) in people with endometrial cancer. Rinatabart Sesutecan (Rina-S), also known ...
Phase
Interventional
-
A Phase 3 Multi-regional Open-label Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
This is a Phase 3 study testing how well and how safely tirabrutinib (a second-generation BTK inhibitor) alone works compared with R-TMZ (rituximab plus temozolomide ...
Phase
Interventional
-
Phase III trial of radiotherapy followed by adjuvant temozolomide in combination with the IDH inhibitor vorasidenib vs. placebo in IDH-mutated newly-diagnosed grade 3 astrocytoma
This is a Phase III study for people with newly diagnosed grade 3 astrocytoma that has a mutation in the IDH (mIDH) gene. All participants ...
Phase
Interventional
-
CAN-2409-LuTK03: A Phase 3 Multicenter Randomized Open Label Clinical Trial of aglatimagene besadenovec (CAN 2409) Plus Prodrug and Pembrolizumab Versus Docetaxel in Patients with Stage IV Non Squamous Non Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment
This is a global, Phase 3 study testing a new treatment for adults with stage IV non-squamous non-small cell lung cancer (NSCLC) whose cancer has ...
Phase
Interventional
